Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP372114.RAwIKW5wIeFmcoO9vpeAeY14fGa1gR8-bjsmvO_kU16sI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP372114.RAwIKW5wIeFmcoO9vpeAeY14fGa1gR8-bjsmvO_kU16sI130_assertion type Assertion NP372114.RAwIKW5wIeFmcoO9vpeAeY14fGa1gR8-bjsmvO_kU16sI130_head.
- NP372114.RAwIKW5wIeFmcoO9vpeAeY14fGa1gR8-bjsmvO_kU16sI130_assertion description "[The drug also decreased levels of phosphorylated Akt, mammalian target of Rapamycin (mTOR), and eukaryotic translation initiation factor 4E binding protein (eIF4E-BP) and lowered the cap site binding activity of eIF4E in the MCL cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP372114.RAwIKW5wIeFmcoO9vpeAeY14fGa1gR8-bjsmvO_kU16sI130_provenance.
- NP372114.RAwIKW5wIeFmcoO9vpeAeY14fGa1gR8-bjsmvO_kU16sI130_assertion evidence source_evidence_literature NP372114.RAwIKW5wIeFmcoO9vpeAeY14fGa1gR8-bjsmvO_kU16sI130_provenance.
- NP372114.RAwIKW5wIeFmcoO9vpeAeY14fGa1gR8-bjsmvO_kU16sI130_assertion SIO_000772 17606765 NP372114.RAwIKW5wIeFmcoO9vpeAeY14fGa1gR8-bjsmvO_kU16sI130_provenance.
- NP372114.RAwIKW5wIeFmcoO9vpeAeY14fGa1gR8-bjsmvO_kU16sI130_assertion wasDerivedFrom befree-20150227 NP372114.RAwIKW5wIeFmcoO9vpeAeY14fGa1gR8-bjsmvO_kU16sI130_provenance.
- NP372114.RAwIKW5wIeFmcoO9vpeAeY14fGa1gR8-bjsmvO_kU16sI130_assertion wasGeneratedBy ECO_0000203 NP372114.RAwIKW5wIeFmcoO9vpeAeY14fGa1gR8-bjsmvO_kU16sI130_provenance.